Riassunto analitico
The application of 3D printing technology in the pharmaceutical industry represents a promising approach for drug formulation and delivery, offering innovative solutions that improve the efficacy, precision, and customization of therapies. This study explores the utilization of FDM coupled with HME for creating accelerated release and dose-adaptable pharmaceutical forms, with the aim of maintaining an extrusion temperature below 100°C to enable the inclusion of thermo-sensitive APIs without compromising their stability and efficacy.
A filament preparation by HME was carried out, aiming at printability, low temperature extrusion and low dissolution time. Using materials already cited in the literature in this field, innovative formulations have been conceived. Soluplus emerged as the most suitable polymer among others for the objective, mixed with plasticizer and disintegrant to enhance performance. However, further refinement of the filament composition is needed in order to reduce the disaggregation time of the tablets obtained from them.
|
